SCHEMBL8627414

SCHEMBL8627414

CCC1=NS(=O)(=O)c2cnccc2N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 5/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
THRB P10828 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2D6 P10635 1/20 0.35
TSHR P16473 1/20 0.35
ABCC8 Q09428 1/20 0.35
KCNJ11 Q14654 1/20 0.35
NAMPT P43490 1/20 0.34
MAPT P10636 3/20 0.33
CA14 Q9ULX7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL8629245 0.87 ALDH1A1 (0.37) ALDH1A1CA12CA1CA2CA9
SCHEMBL8761102 0.82 ALDH1A1 (0.41) ALDH1A1CA12CA1CA2CA9
SCHEMBL8761359 0.81 ALDH1A1 (0.45) ALDH1A1CA12CA1CA2CA9
SCHEMBL394795 0.79 ALDH1A1 (0.39) ALDH1A1MEN1USP2KMT2ALMNA
SCHEMBL8286622 0.79 CA12 (0.62) ALDH1A1CA12CA1CA2CA9
SCHEMBL393052 0.79 ALDH1A1 (0.38) ALDH1A1CA12CA1CA2CA9
SCHEMBL6618015 0.76 CA12 (0.34) ALDH1A1CA12CA1CA2CA9
SCHEMBL8631741 0.76 CA12 (0.38) ALDH1A1CA12CA1CA2CA9
SCHEMBL8624743 0.75 CA12 (0.38) ALDH1A1CA12CA1CA2CA9
SCHEMBL14077410 0.75 CA12 (0.38) ALDH1A1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7425552-B2 Antiviral agent especially to treat hepatitis C virus infections; 5-Hydroxy-4-(7-methoxy-1,1-dioxo-1,2-dihydro-1 lambda 6-benzo[1,2,4]thiadiazin-3-yl)-2-(3-methyl-butyl)-6-thiophen-2-yl-2H-py-ridazin-3-one; side effects reduction ANADYS PHARMACEUTICALS, INC. (US) 2008-09-16 US disclosed
EP-0618209-B1 Pyridothiadiazines, processes for their preparation and pharmaceutical compositions containing them ADIR (FR) 1998-12-23 EP disclosed
US-5459138-A Dysfunctions of glutamatergic neurotransmission associated with learning and memory ADIR ET COMPAGNIE (FR) 1995-10-17 US disclosed
EP-0618209-A1 Pyridothiadiazines, processes for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1994-10-05 EP disclosed